Addison, Illinois 60101

  • Primary Hypercholesterolemia


The objectives of this study are to assess the effects of 4 g/d P-OM3, compared with placebo, on LDL-C and other aspects of the fasting lipid profile in subjects with primary hypercholesterolemia.

Study summary:

This trial will utilize a randomized, double-blind, two-period crossover design. At Visit 2 (Week 0), subjects meeting all entry criteria will be randomized to one of two treatment sequences: placebo or P-OM3 for the first 6 week phase followed by the study product they did not receive during the first phase (P-OM3 or placebo) for the second 6 weeks.


Inclusion Criteria: - Men and women, ages 18-79 inclusive - Fasting, untreated low-density lipoprotein cholesterol (LDL-C)level in the borderline high to very high range - Fasting, untreated triglyceride (TG)level in the normal range - Provide written informed consent and authorization for protected health information Exclusion Criteria: - CHD or CHD risk equivalent - Pregnancy - Use of lipid altering medications which cannot be stopped - Body mass index over 45 kg per square meter - Allergy or sensitivity to omega-3 fatty acids - Certain muscle, liver, kidney, lung or gastrointestinal conditions - Poorly controlled hypertension - Certain medications - Active cancers treated within prior 2 years (except non-melanoma skin cancer)



Primary Contact:

Study Director
Kevin C. Maki, PhD
Provident Clinical Research

Backup Contact:


Location Contact:

Addison, Illinois 60101
United States

John Marshall, RN, BSN
Phone: 630-617-2000

Site Status: Recruiting

Data Source:

Date Processed: September 18, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.